AUTHORS | STUDY | NOS | ARMS OF THE STUDY | CONCLUSIONS |
Ichihara et al (7)
|
RC
|
76
|
Tamsulosin 0.2mg + Mirabegron 50mg vs Tamsulosin 0.2mg (8 weeks) |
Combination therapy with tamsulosin& mirabegron was effective in BPH
with residual OABS postinitiation of tamsulosin
|
Kakizaki et al (8)
|
RC
|
568
|
Tamsulosin 0.2mg + Mirabegron 50mg Vs Tamsulosin 0.2mg+placebo (12 weeks) |
Mirabegron add-on therapy to tamsulosin for 12wk in men with LUTS &
OABS demonstrated superior efficacy to placebo with good tolerance
|
Kaplan et al (9)
|
RC
|
676
|
Tamsulosin 0.4mg + Mirabegron 50mg Vs Tamsulosin 0.4mg + placebo (12 weeks) |
Mirabegron add on therapy was statistically significant in reducing OABS
in comparison to placebo
|
Shunye Su et al (10)
|
MA
|
1317
|
Mirabegron + tamsulosin vs Tamsulosin (8-12 weeks) |
Mirabegron was effective and safe treatment for OABS induced by BPH in
men receiving tamsulosin therapy with a low occurrence of side
effects.
|
Matsuo et al (11)
|
PA
|
50
|
Analysis of Mirabegron (50mg) add on therapy to α1 adrenergic blocker. (12 weeks) |
Mirabegron add on therapy was effective in persistent OABS after α1
blockers in men with BPH.
|
Wada et al (12)
|
PA
|
26
|
Analysis of Mirabegron (50mg) add on therapy to pre-existing tamsulosin. (8 weeks) |
Mirabegron add on treatment with tamsulosin was efficacious/safe in
improving OABS without impairing bladder contractility in men with
OAB.
|
Present Study
|
RC
|
100
|
Tamsulosin 0.4mg + Mirabegron 50mg vs Tamsulosin 0.4mg+Placebo(8 weeks) |
Mirabegron & tamsulosin combination therapy was significantly
efficacious and safe versus Tamsulosin monotherapy for BPH induced OABS
without an increase in PVR/AUR.
|
PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms | PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms | PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms | PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms | PA-Prospective Analysis, MA-Metanalysis, RC- Randomised controlled study, AUR-Acute urinary retention, PVR-Post void residue, OABS-Overactive bladder symptoms |